The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer

Lung cancer (LC) is the deadliest malignancy worldwide. In an operable stage I–III patient setting, the detection of minimal residual disease (MRD) after curative treatment could identify patients at higher risk of relapse. In this context, the study of circulating tumor DNA (ctDNA) is emerging as a...

Descripció completa

Dades bibliogràfiques

Autors principals:	Alberto Verlicchi, Matteo Canale, Elisa Chiadini, Paola Cravero, Milena Urbini, Kalliopi Andrikou, Luigi Pasini, Michele Flospergher, Marco Angelo Burgio, Lucio Crinò, Paola Ulivi, Angelo Delmonte
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2023-09-01
Col·lecció:	Life
Matèries:	non-small cell lung cancer minimal residual disease circulating tumor DNA
Accés en línia:	https://www.mdpi.com/2075-1729/13/9/1915
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!